Navigation Links
Heart Failure: Targeting the right patients for CRT-D
Date:5/22/2011

Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial. The CRT-MADIT-CRT trial - presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (ESC) in Late Breaking Session 1 - showed that CRT produced improvements in both synchrony and contractile function, and that the extent of this benefit relates to subsequent outcomes.

The Multicentre Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT) set out to determine whether patients with mild heart failure (NYHA class I or II) would do better if they got implanted with a CRT-D device (which combines cardiac resynchronization therapy with defibrillation), than if they only received the traditional ICD defibrillation. In earlier studies CRT-D devices had been approved for use in patients with severe heart failure (NYHA class III/IV).

In the MADIT-CRT study, funded by Boston Scientific, 1820 patients with Class I and II heart failure, wide QRS and left ventricular dysfunction were randomized 3:2 to receive CRT-D (n=1089) or ICD alone (n=731). Results, presented at the 2009 ESC Annual Conference in Barcelona after a follow period averaging 2.4 years, demonstrated a greater than 40% reduction in the primary endpoint of death or heart failure in patients receiving CRT-D. However, in virtually all studies of CRT-D approximately 30% of patients do not respond to therapy.

In the current study, Dr Scott D Solomon (Brigham and Women's Hospital, Boston, MA) and colleagues set out to investigate whether the degree of synchrony the extent to which the walls of the left ventricle contract in unison might influence the likelihood of patients responding to CRT-D. "It's important to target patients in whom CRT-D works well because the technology is quite expensive," explained Solomon.

In this latest analysis of MADIT-CRT, investigators analyzed echocardiograms from 1077 patients enrolled in MADIT-CRT (CRT-D n=66; ICD, n=416) who had echocardiographic images of sufficient quality to allow analysis of synchrony and contractile function. Researchers were blinded to the randomization and study outcomes.

Results showed that patients with mild to moderate dyssynchrony at baseline (defined as a time-to peak transverse strain SD of 142-230 ms) and greater baseline contractile function (longitudinal strain < -8.7%) improved to a greater extent when randomised to the CRT-D group than the ICD only group.

The study showed that over a year each 10 ms decrease in LV dyssynchrony was associated with a 3% reduction in the primary outcome of death or heart failure, and each 5 point absolute increase in LV strain was associated with a 75% reduction in the primary outcome.

"These results suggest that the patients who are most likely to benefit from CRT-D are those with at least some dyssynchrony who have relatively preserved contractile function," said Solomon, adding that the observation that improvements in synchrony and contractile function were associated with reduced death and heart failure events, suggests that the benefits delivered by CRT relate to improvements in these factors. "Future studies will continue to try to identify the patients who are most likely to benefit from this expensive but highly effective therapy," he said.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-492-947-756
European Society of Cardiology
Source:Eurekalert

Related biology news :

1. Dark chocolate: Half a bar per week to keep at bay the risk of heart attack
2. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
3. Researchers study how pistachios may improve heart health
4. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
5. LIAI launches new division to look at novel approaches to heart disease and inflammation
6. Study provides insight on a common heart rhythm disorder
7. Embryonic heart exhibits impressive regenerative capacity
8. Repair in the developing heart
9. Drug-embedded microparticles bolster heart function in animal studies
10. Heart valves that grow with the patient
11. Research uncovers new steps on pathway to enlarged heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2020)... (PRWEB) , ... August 11, 2020 , ... ... subsidiary based in Princeton, NJ, have entered into license agreements with Housey Pharma’s ... development. Both Roche and J&J have annual Research and Development spending in ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the Centers ... making them the first Wharton’s jelly allografts to be assigned a Q code and ... are the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P ...
(Date:7/22/2020)... ... July 21, 2020 , ... USDM Life Sciences , ... announces a new solution to manage regulated workloads on Microsoft Azure. , Regulated ... stack complies with FDA and global regulations. USDM's new managed service for regulated ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 12, 2020 , ... ... International), a global leader in FDA compliance consulting has been named on its ... companies. The list represents a unique look at the most successful companies within ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands ... , Known as MediVet Biologics since its formation in 2016, the company is ... Animal Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... BEDFORD, Mass. (PRWEB) , ... July 29, 2020 ... ... of highly reliable, solid-state radar transmitter systems that can be configured to drive ... a single controller that can drive one or two switches in a push-pull ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management ... reasons it did not take off as quickly as people initially expected, and where ... towards capturing data electronically for clinical trials and then repurposing it for downstream analysis, ...
Breaking Biology Technology: